+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia Pacific Synthetic Small Molecule API Market Size, Share & Industry Trends Analysis Report by Manufacturer, Application, Country and Growth Forecast, 2022-2028

  • PDF Icon

    Report

  • 86 Pages
  • September 2022
  • Region: Asia Pacific
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5673481
The Asia Pacific Synthetic Small Molecule API Market would witness market growth of 6.0% CAGR during the forecast period (2022-2028).

A technique called gas-phase hydrogen-deuterium exchange in conjunction with ion mobility spectrometry-mass spectrometry (IMS-MS) has been used to analyze novel psychoactive substances (NPSs), which are tiny synthetic chemicals created to mimic the effects of other illegal narcotics. Here, the HDX reactivity of NPSs with labile heteroatom hydrogens was assessed in the drift tube with either deuterated water (D2O) or ammonia (ND3). Six NPSs underwent a preliminary study of exchange propensity.

In the presence of ND3, five compounds were exchanged, but only one NPS (benzyl piperazine) was transferred with D2O. The diamine ring of benzyl piperazine offered this charging site at a set length since the exchange mechanism of D2O needs stabilization with a neighboring charged site. O, M, and P-fluorophenyl piperazine, three disubstituted benzene isomers, contain the diamine.

These isomers could not be differentiated from one another by IMS-MS alone due to their same isotopic content and nearly identical drift time distributions. A test of means following HDX in the drift tube, however, revealed that differentiation was feasible if the exchange data from both reagent gases were considered. The observed exchange disparities may partially be explained by the fact that molecular dynamics simulations reveal that the fluorine's proximity to the diamine ring prevents the benzene and diamine ring from rotating at the same dihedral angle.

The market for molecular quality controls is in good shape as a result of the consistently growing demand for accurate and high-quality diagnostic tests. The need for precision oncology has become a prominent focus of various authorities in the region, leading to the formation of multiple projects, as cancer is becoming a more prevalent health issue in the APAC region as a result of aging populations and lifestyle changes. These programs include the Japanese LC-SCRUM lung cancer genomic screening project and the South Korean K-MASTER (Korean Cancer Precision Medicine Diagnosis and Treatment Enterprise) platform.

The China market dominated the Asia Pacific Synthetic Small Molecule API Market by Country in 2021; thereby, achieving a market value of $14,660.4 million by 2028. The Japan market is experiencing a CAGR of 5.3% during (2022-2028). Additionally, The India market is exhibiting a CAGR of 6.6% during (2022-2028).

Based on Manufacturer, the market is segmented into In-house and Outsourced. Based on Application, the market is segmented into Cardiology, Oncology, CNS & Neurology, Endocrinology, Orthopedic, Gastroenterology, Pulmonology, Nephrology, Ophthalmology, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Viatris, Inc., Cipla Limited, Teva Pharmaceuticals Industries Ltd., Sun Pharmaceuticals Industries Ltd., AbbVie, Inc., Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited and Albermale Corporation.

Scope of the Study

Market Segments Covered in the Report:

By Manufacturer

  • In-house
  • Outsourced

By Application

  • Cardiology
  • Oncology
  • CNS & Neurology
  • Endocrinology
  • Orthopedic
  • Gastroenterology
  • Pulmonology
  • Nephrology
  • Ophthalmology
  • Others

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

  • Merck & Co., Inc.
  • Viatris, Inc.
  • Cipla Limited
  • Teva Pharmaceuticals Industries Ltd.
  • Sun Pharmaceuticals Industries Ltd.
  • AbbVie, Inc.
  • Bristol Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Aurobindo Pharma Limited
  • Albermale Corporation

Unique Offerings from the Publisher

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Synthetic Small Molecule API Market, by Manufacturer
1.4.2 Asia Pacific Synthetic Small Molecule API Market, by Application
1.4.3 Asia Pacific Synthetic Small Molecule API Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Synthetic Small Molecule API Market by Manufacturer
3.1 Asia Pacific In-house Market by Country
3.2 Asia Pacific Outsourced Market by Country
Chapter 4. Asia Pacific Synthetic Small Molecule API Market by Application
4.1 Asia Pacific Cardiology Market by Country
4.2 Asia Pacific Oncology Market by Country
4.3 Asia Pacific CNS & Neurology Market by Country
4.4 Asia Pacific Endocrinology Market by Country
4.5 Asia Pacific Orthopedic Market by Country
4.6 Asia Pacific Gastroenterology Market by Country
4.7 Asia Pacific Pulmonology Market by Country
4.8 Asia Pacific Nephrology Market by Country
4.9 Asia Pacific Ophthalmology Market by Country
4.1 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Synthetic Small Molecule API Market by Country
5.1 China Synthetic Small Molecule API Market
5.1.1 China Synthetic Small Molecule API Market by Manufacturer
5.1.2 China Synthetic Small Molecule API Market by Application
5.2 Japan Synthetic Small Molecule API Market
5.2.1 Japan Synthetic Small Molecule API Market by Manufacturer
5.2.2 Japan Synthetic Small Molecule API Market by Application
5.3 India Synthetic Small Molecule API Market
5.3.1 India Synthetic Small Molecule API Market by Manufacturer
5.3.2 India Synthetic Small Molecule API Market by Application
5.4 South Korea Synthetic Small Molecule API Market
5.4.1 South Korea Synthetic Small Molecule API Market by Manufacturer
5.4.2 South Korea Synthetic Small Molecule API Market by Application
5.5 Singapore Synthetic Small Molecule API Market
5.5.1 Singapore Synthetic Small Molecule API Market by Manufacturer
5.5.2 Singapore Synthetic Small Molecule API Market by Application
5.6 Malaysia Synthetic Small Molecule API Market
5.6.1 Malaysia Synthetic Small Molecule API Market by Manufacturer
5.6.2 Malaysia Synthetic Small Molecule API Market by Application
5.7 Rest of Asia Pacific Synthetic Small Molecule API Market
5.7.1 Rest of Asia Pacific Synthetic Small Molecule API Market by Manufacturer
5.7.2 Rest of Asia Pacific Synthetic Small Molecule API Market by Application
Chapter 6. Company Profiles
6.1 Merck & Co., Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expenses
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.2 Viatris, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 Cipla Limited
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expense
6.4 Teva Pharmaceutical Industries Ltd.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.5 Sun Pharmaceuticals Industries Ltd.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Regional Analysis
6.5.4 Research & Development Expenses
6.6 AbbVie, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.7 Bristol Myers Squibb Company
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expenses
6.8 Boehringer Ingelheim International Gmbh
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional & Segmental Analysis
6.8.4 Research & Development Expenses
6.9 Aurobindo Pharma Limited
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.10. Albemarle Corporation
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental Analysis
6.10.4 Research & Development Expenses

Companies Mentioned

  • Merck & Co., Inc.
  • Viatris, Inc.
  • Cipla Limited
  • Teva Pharmaceuticals Industries Ltd.
  • Sun Pharmaceuticals Industries Ltd.
  • AbbVie, Inc.
  • Bristol Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Aurobindo Pharma Limited
  • Albermale Corporation

Methodology

Loading
LOADING...